Eli Lilly stock gains as Foundayo supports sleep-apnea filing

Eli Lilly and Company said on Monday, November 9, that its oral GLP-1 drug Foundayo significantly reduced obstructive sleep apnea severity in the Phase 3 ATTAIN-OSA program. The company said it plans to submit the drug to the US Food and Drug Administration for moderate-to-severe sleep apnea in adults with obesity or overweight by the end of 2026.

According to Eli Lilly's news release, the results covered 52 weeks and were presented at the 2026 American Heart Association Scientific Sessions while also being published in JAMA. The trial met its primary endpoint, reducing the apnea-hypopnea index, the standard measure of breathing interruptions during sleep.

Sleep-apnea results widen the opportunity

In the study group that did not use positive airway pressure therapy, Foundayo reduced apnea-hypopnea index events by 21.1 per hour, or 43.8%, from a baseline of 50.7 events per hour. The placebo reduction was 4.3 events per hour, or 6.3%. A total of 47.2% of participants receiving Foundayo achieved at least a 50% reduction in the index, while 31.5% reached remission or mild disease under the trial's criteria.

Among participants who continued positive airway pressure therapy, Foundayo reduced apnea-hypopnea index events by 18.3 per hour, or 27.5%, from a baseline of 57.6 events per hour. The corresponding placebo reduction was 5.5 events per hour, or 3.0%. In this group, 33.7% achieved at least a 50% reduction and 19.6% reached remission or mild disease.

The results extend beyond breathing interruptions. Lilly said sleep-apnea-specific hypoxic burden fell by 55.9% without positive airway pressure and by 45.8% with it. Average body weight declined by 11.5% in the first group and 11.2% in the second, equivalent to 28.0 pounds and 28.2 pounds. Systolic blood pressure fell by 8.6 and 7.3 millimeters of mercury, while the inflammation marker hsCRP declined by 48.9% and 38.6%, respectively.

Regulatory execution remains next catalyst

For investors, the planned filing is the next clearly defined step. Foundayo is already approved in the United States for adults with obesity, and a sleep-apnea label could broaden its commercial role beyond weight management. The program also gives Lilly another oral option in a market where treatment choice, convenience and cardiovascular risk are important factors.

Safety remained a central consideration. Lilly said gastrointestinal events such as nausea, diarrhea, constipation, indigestion and vomiting were generally mild to moderate. Discontinuation because of adverse events occurred in 12.2% of Foundayo participants versus 3.8% on placebo without positive airway pressure, and in 6.8% versus 0.6% among those using the therapy.

Eli Lilly stock traded at 1,319.50 euros on Lang & Schwarz at 14:12 CET on Thursday, November 12, 2026, 2.89% above the Xetra close of Wednesday, November 11, at 1,282.40 euros.

The broader market context for Lilly stock is available in the current market reports.

More news and analyses on Eli Lilly and Company stock.